Dr. Nathaniel Buteyn earned his Ph.D. in molecular, cellular and developmental biology from Ohio State University and his B.S. in biotechnology from Calvin College. His graduate work focused on the development of novel immunotherapies for the treatment of acute myeloid leukemia. These included inducing fratricidal blast-to-blast killing utilizing anti-CD38 monoclonal antibody Daratumumab in conjunction with all-trans retinoic acid and the reactivation of innate immunity/NK cell cytotoxicity through activation of the intracellular pathogen recognition receptor NOD2 with a synthetic bacterial peptide, muramyl tripeptide phosphatidylethanolamine. Dr. Buteyn’s lab skills include mammalian cell culture, murine drug models, qPCR, Western blots, cytotoxicity assays and flow cytometry. In 2020, he joined the lab of Dr. Tim Triche, Jr., as a postdoctoral fellow.